Conclusion

Europe should take China’s ambition seriously, without assuming that every China-only result will apply everywhere or asking Chinese companies to repeat the entire development journey in Europe. Nor should Europe assume that global credibility must - or will - always be earned in Europe or the US. Europe can add most value much earlier, by helping decide what evidence needs to be collected globally, what can reasonably be carried across markets, and which clinical questions should be addressed before the final trial design is set. China is increasingly ready to lead development. Europe can still influence where that development leads, but only by getting involved early enough to shape the decisions.


To learn how Chinese biopharma innovation is reshaping the rules of engagement in global oncology, read: From Spark to Inferno.

Find out more

Contact us
About the research

Inspiring Better Healthcare

Ipsos Rx Insight Store

Contact us

About the Research

Privacy

Cookie Policy